Amol Akhade, Senior consultant medical oncologist and hemato-oncologist at Suyog Cancer Clinics and Reliance Hospital, shared a post on LinkedIn:
“Today is day of press release.
Sacituzumab govitecan plus pembrolizumab shows PFS benefit over chemo plus Pembrolizumab in metastatic TNBC with CPS > 10.
Ascent 04 trial.
Looking forward to Magnitude of benifit.”
